BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//LifeSci Events - ECPv6.15.11//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:LifeSci Events
X-ORIGINAL-URL:https://lifescievents.com
X-WR-CALDESC:Events for LifeSci Events
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20270314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20271107T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260928T123000
DTEND;TZID=America/New_York:20260928T140000
DTSTAMP:20260901T222129
CREATED:20260728T160510Z
LAST-MODIFIED:20260901T180702Z
UID:3205-1790598600-1790604000@lifescievents.com
SUMMARY:Quince Therapeutics Virtual KOL Event to Discuss the Current Treatment Landscape for PH-ILD and BOS and the Potential Role for LAM-001 as a New Therapeutic Option
DESCRIPTION:Join Quince Therapeutics for a virtual key opinion leader (KOL) event featuring PH-ILD experts Aaron B. Waxman\, MD\, PhD (Brigham and Women’s Hospital) and Paul Yu\, MD\, PhD (Massachusetts General Hospital)\, as well as BOS expert Steven Hays\, MD (UCSF Health)\, who will join company management to discuss the unmet need and current treatment landscape for PH-ILD and BOS. \nThe event will provide an overview of LAM-001\, the Company’s proprietary once-daily inhaled DPI formulation of rapamycin (mTOR inhibitor)\, currently in Phase 2 clinical trials for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and bronchiolitis obliterans syndrome post lung transplant (BOS). The KOLs will discuss mTOR inhibition as a potentially disease-modifying mechanism of action across these conditions\, focusing on its role in suppressing pulmonary smooth-muscle hyperproliferation\, limiting fibroblast-driven vascular and interstitial remodeling\, and modulating inflammatory signaling\, along with the unique potential advantages of delivering therapy through an inhaled route. Data from the recently presented Phase 2a trial of LAM-001 in pulmonary hypertension will be reviewed as well as the design and objectives of the ongoing Phase 2 BOS and Phase 2b PH-ILD studies. \nA live question and answer session will follow the formal presentations. Watch the webcast by clicking this link and logging in with the email address you used to register: https://lifescievents.com/event/gr59hlp/.
URL:https://lifescievents.com/event/gr59hlp/
LOCATION:Virtual\, Virtual
ATTACH;FMTTYPE=image/png:https://lifescievents.com/wp-content/uploads/2026/07/Events-Banners_2-7-1.png
END:VEVENT
END:VCALENDAR